These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9747664)

  • 21. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.
    Olsson S
    Drug Saf; 1998 Jul; 19(1):1-10. PubMed ID: 9673854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
    Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
    Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semantic distance-based creation of clusters of pharmacovigilance terms and their evaluation.
    Dupuch M; Grabar N
    J Biomed Inform; 2015 Apr; 54():174-85. PubMed ID: 25659451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes to adverse drug reactions and their reporting among medical practitioners.
    Robins AH; Weir M; Biersteker EM
    S Afr Med J; 1987 Jul; 72(2):131-4. PubMed ID: 3616786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
    Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Criteria of drug-induced liver disorders. Report of an international consensus meeting.
    Bénichou C
    J Hepatol; 1990 Sep; 11(2):272-6. PubMed ID: 2254635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adverse drug reactions definitions and terminology].
    Rabinovitz H; Berkowitch M; Golik A; Shani S
    Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Founding an adverse drug reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a general hospital.
    Goldstein LH; Berlin M; Saliba W; Elias M; Berkovitch M
    J Clin Pharmacol; 2013 Nov; 53(11):1220-5. PubMed ID: 23852627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying the common genetic networks of ADR (adverse drug reaction) clusters and developing an ADR classification model.
    Hwang Y; Oh M; Jang G; Lee T; Park C; Ahn J; Yoon Y
    Mol Biosyst; 2017 Aug; 13(9):1788-1796. PubMed ID: 28702565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.